Free Trial
TSE:CXR

Concordia International (CXR) Stock Price, News & Analysis

Concordia International logo

About Concordia International Stock (TSE:CXR)

Key Stats

Today's Range
N/A
50-Day Range
C$25.04
C$25.04
52-Week Range
N/A
Volume
73,541 shs
Average Volume
4,054 shs
Market Capitalization
C$1.22 billion
P/E Ratio
0.07
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.

Receive CXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concordia International and its competitors with MarketBeat's FREE daily newsletter.

CXR Stock News Headlines

We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
See More Headlines

CXR Stock Analysis - Frequently Asked Questions

Shares of CXR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Concordia International investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET) and Wheaton Precious Metals (WPM).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Transportation
CIK
N/A
Fax
N/A
Employees
22,500
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$569.62 million
Cash Flow
C$4.28 per share
Book Value
C$6.08 per share

Miscellaneous

Free Float
N/A
Market Cap
C$1.22 billion
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (TSE:CXR) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners